Xin Lang Zheng Quan·2025-09-30 02:58Core Viewpoint - BeiGene's stock price has shown significant volatility and growth in 2023, with a notable increase in revenue and net profit for the first half of the year [2][3]. Stock Performance - As of September 30, BeiGene's stock rose by 2.02% to 307.09 CNY per share, with a trading volume of 5.59 billion CNY and a market capitalization of 473.13 billion CNY [1]. - Year-to-date, BeiGene's stock price has increased by 90.72%, with a 1.17% rise in the last five trading days, a 5.47% decline over the past 20 days, and a 37.62% increase over the last 60 days [2]. Financial Performance - For the period from January to June 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03%, and a net profit attributable to shareholders of 450 million CNY, up 115.63% year-on-year [2]. Shareholder Information - As of June 30, 2025, the number of shareholders for BeiGene was 23,300, a decrease of 3.90% from the previous period, with an average of 4,976 circulating shares per shareholder, an increase of 4.11% [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A and a decrease in holdings by Wan Jia You Xuan [3].